CTi Biopharma Corp Performance
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CTi Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding CTi Biopharma is expected to be smaller as well. CTi Biopharma Corp right now shows a risk of 0.0%. Please confirm CTi Biopharma Corp value at risk, kurtosis, and the relationship between the sortino ratio and semi variance , to decide if CTi Biopharma Corp will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CTi Biopharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound forward indicators, CTi Biopharma is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 65.4 M | |
| Total Cashflows From Investing Activities | -73.9 M |
CTi |
CTi Biopharma Relative Risk vs. Return Landscape
If you would invest 909.00 in CTi Biopharma Corp on September 4, 2024 and sell it today you would earn a total of 0.00 from holding CTi Biopharma Corp or generate 0.0% return on investment over 90 days. CTi Biopharma Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than CTi, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CTi Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CTi Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CTi Biopharma Corp, and traders can use it to determine the average amount a CTi Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CTIC |
Based on monthly moving average CTi Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CTi Biopharma by adding CTi Biopharma to a well-diversified portfolio.
CTi Biopharma Fundamentals Growth
CTi Stock prices reflect investors' perceptions of the future prospects and financial health of CTi Biopharma, and CTi Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CTi Stock performance.
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 112.63 X | |||
| Price To Sales | 22.01 X | |||
| Revenue | 53.95 M | |||
| EBITDA | (79.85 M) | |||
| Cash And Equivalents | 81.64 M | |||
| Cash Per Share | 0.64 X | |||
| Total Debt | 49.96 M | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (81.19 M) | |||
| Earnings Per Share | (0.54) X | |||
| Total Asset | 125.92 M | |||
| Retained Earnings | (2.52 B) | |||
| Current Asset | 134.97 M | |||
| Current Liabilities | 72.41 M | |||
About CTi Biopharma Performance
By analyzing CTi Biopharma's fundamental ratios, stakeholders can gain valuable insights into CTi Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CTi Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CTi Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.Things to note about CTi Biopharma Corp performance evaluation
Checking the ongoing alerts about CTi Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CTi Biopharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CTi Biopharma Corp is not yet fully synchronised with the market data | |
| CTi Biopharma Corp has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 53.95 M. Net Loss for the year was (92.99 M) with profit before overhead, payroll, taxes, and interest of 50.43 M. | |
| CTi Biopharma Corp currently holds about 81.64 M in cash with (81.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
- Analyzing CTi Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CTi Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining CTi Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CTi Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CTi Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CTi Biopharma's stock. These opinions can provide insight into CTi Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world |